IL2 and renal cell carcinoma: RCC patients whose TMA shows positive expression of B7-H4 must not select IFN-α/IL-2 treatment alone, since the T-cell-mediated antitumor responses must have been repressed by the B7-H4 mediated immune escape pathway.